Phosphagenics signs agreement with Alza to fund tests on skin gel

New York, Nov. 7 - Phosphagenics Ltd. said it has signed a development agreement under which Alza Corp. will fund tests on delivering compounds with Phosphagenics' transdermal delivery system TPM-01.

"Phosphagenics' transdermal technology is globally competitive and uniquely safe and effective, and has the potential to be applied to an extraordinary range of drugs," said Esra Ogru, Phosphagenics' director of research and development, in a news release.

"Our technology has previously been tested on a number of drugs, and has successfully delivered insulin, parathyroid hormone, fentanyl, morphine, estradiol, testosterone and atropine across animal skin."

TPM-01 is a gel applied to the skin. In April a phase I clinical trial showed it to be effective in delivering morphine into the bloodstream through human skin. Phase I trials with insulin are planned to start in the first quarter of 2006.

Alza will pick the compounds to be tested under the new agreement.

Phosphagenics is a Melbourne, Australia, pharmaceutical and neutraceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.